Luyan Pharma Co.,Ltd. (002788.SZ)
CNY 8.03
(-0.5%)
CNY 8.03
(-0.5%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 4.23 Billion CNY | -5.22% |
| 2022 | 4.46 Billion CNY | 10.13% |
| 2021 | 4.05 Billion CNY | 40.54% |
| 2020 | 2.88 Billion CNY | 2.18% |
| 2019 | 2.82 Billion CNY | 61.0% |
| 2018 | 1.75 Billion CNY | 40.23% |
| 2017 | 1.25 Billion CNY | 154.12% |
| 2016 | 492.31 Million CNY | -28.23% |
| 2015 | 685.97 Million CNY | 25.11% |
| 2014 | 548.27 Million CNY | -3.4% |
| 2013 | 567.54 Million CNY | 115.52% |
| 2012 | 263.34 Million CNY | 159.41% |
| 2011 | 101.51 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 5.59 Billion CNY | 22.09% |
| 2024 Q3 | 4.36 Billion CNY | -20.02% |
| 2024 Q1 | 4.57 Billion CNY | 8.15% |
| 2023 Q3 | 4.69 Billion CNY | 1.03% |
| 2023 Q4 | 4.23 Billion CNY | -9.76% |
| 2023 FY | 4.23 Billion CNY | -5.22% |
| 2023 Q1 | 4.7 Billion CNY | 5.27% |
| 2023 Q2 | 4.64 Billion CNY | -1.26% |
| 2022 Q4 | 4.46 Billion CNY | 1.07% |
| 2022 Q3 | 4.41 Billion CNY | 3.28% |
| 2022 Q2 | 4.27 Billion CNY | -7.49% |
| 2022 Q1 | 4.62 Billion CNY | 14.04% |
| 2022 FY | 4.46 Billion CNY | 10.13% |
| 2021 Q1 | 3.65 Billion CNY | 26.48% |
| 2021 Q2 | 3.79 Billion CNY | 4.0% |
| 2021 Q3 | 3.95 Billion CNY | 4.1% |
| 2021 Q4 | 4.05 Billion CNY | 2.63% |
| 2021 FY | 4.05 Billion CNY | 40.54% |
| 2020 Q4 | 2.88 Billion CNY | -8.59% |
| 2020 Q1 | 3.33 Billion CNY | 18.12% |
| 2020 Q2 | 3.18 Billion CNY | -4.55% |
| 2020 FY | 2.88 Billion CNY | 2.18% |
| 2020 Q3 | 3.15 Billion CNY | -0.85% |
| 2019 Q4 | 2.82 Billion CNY | -2.43% |
| 2019 FY | 2.82 Billion CNY | 61.0% |
| 2019 Q3 | 2.89 Billion CNY | 6.64% |
| 2019 Q2 | 2.71 Billion CNY | 7.24% |
| 2019 Q1 | 2.53 Billion CNY | 44.29% |
| 2018 FY | 1.75 Billion CNY | 40.23% |
| 2018 Q1 | 1.85 Billion CNY | 48.52% |
| 2018 Q2 | 1.81 Billion CNY | -2.18% |
| 2018 Q3 | 1.99 Billion CNY | 10.03% |
| 2018 Q4 | 1.75 Billion CNY | -12.27% |
| 2017 Q1 | 653.75 Million CNY | 32.79% |
| 2017 Q2 | 1.39 Billion CNY | 113.73% |
| 2017 FY | 1.25 Billion CNY | 154.12% |
| 2017 Q4 | 1.25 Billion CNY | -26.75% |
| 2017 Q3 | 1.7 Billion CNY | 22.24% |
| 2016 Q4 | 492.31 Million CNY | -49.85% |
| 2016 Q3 | 981.68 Million CNY | -7.95% |
| 2016 Q2 | 1.06 Billion CNY | 37.31% |
| 2016 Q1 | 776.63 Million CNY | 13.22% |
| 2016 FY | 492.31 Million CNY | -28.23% |
| 2015 Q3 | 1.08 Billion CNY | 0.0% |
| 2015 Q4 | 685.97 Million CNY | -36.83% |
| 2015 FY | 685.97 Million CNY | 25.11% |
| 2015 Q1 | 579.7 Million CNY | 0.0% |
| 2014 FY | 548.27 Million CNY | -3.4% |
| 2013 FY | 567.54 Million CNY | 115.52% |
| 2012 FY | 263.34 Million CNY | 159.41% |
| 2011 FY | 101.51 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Cachet Pharmaceutical Co., Ltd. | 1.13 Billion CNY | -273.625% |
| Yixintang Pharmaceutical Group Co., Ltd. | 1.21 Billion CNY | -249.782% |
| ZJAMP Group Co., Ltd. | -2.65 Billion CNY | 259.621% |
| Ji Yao Holding Group Co., Ltd. | 1.42 Billion CNY | -197.989% |